Papers

3

Total Citations

115

H-Index

3

About

Aaron Bradshaw is a leading urologic oncologist whose research focuses on optimizing surgical outcomes for renal cell carcinoma, particularly through the advancement of robotic partial nephrectomy. His major contributions center on demonstrating the safety and efficacy of minimally invasive approaches for complex kidney tumors. In a landmark 2020 study from the ROSULA Collaborative Group, Bradshaw compared robotic partial nephrectomy (RAPN) to minimally invasive radical nephrectomy for clinical T2a renal masses, showing that nephron-sparing surgery can be performed effectively for larger tumors—a finding that has garnered 64 citations and influenced treatment paradigms. His 2019 single-surgeon analysis further established that RAPN achieves superior trifecta outcomes (negative margins, minimal complications, and warm ischemia time) compared to open surgery for T2a disease. Additionally, Bradshaw’s multi-institutional work on upstaging to pT3a disease in cT1 kidney cancer has provided critical insights into predictors of aggressive pathology, helping refine patient selection for robotic approaches. With over 100 cumulative citations, Bradshaw’s research has been instrumental in expanding the role of robotic surgery for renal masses, offering patients less invasive options without compromising oncologic control.

Research Focus

Key Achievements

3
H-Index
3
Papers
115
Total Citations
38
Avg Citations/Paper
🏆 Most Cited Paper
Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score‐matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group
64 citations · 2020
📈 Most Prolific Year: 2020 (2 Papers)
🤝 Key Collaborators: 51
🏛 Institutions: University of California San Diego, UC San Diego Health System

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago